Fig. 4: ctDNA testing is predictive of the benefit of ACT in postsurgical patients with colorectal cancer. | npj Precision Oncology

Fig. 4: ctDNA testing is predictive of the benefit of ACT in postsurgical patients with colorectal cancer.

From: Validation of a methylation-based, tissue-free MRD assay in colorectal cancer patients from the GALAXY study

Fig. 4: ctDNA testing is predictive of the benefit of ACT in postsurgical patients with colorectal cancer.

a Kaplan–Meier analysis of DFS stratified by adjuvant treatment (observation versus ACT) in ctDNA-positive and -negative patients with pathological high-risk stage II or stage III colorectal cancer. b Kaplan-Meier analysis of DFS and plasma ctDNA status in all patients who underwent ACT. The barplot shows the association between ctDNA status during ACT and relapse during the study period.

Back to article page